Photo of Paolo Tarantino taken from Twitter
Mar 15, 2024, 18:24
Paolo Tarantino: Final analysis of the PEONY phase 3 trial
Paolo Tarantino, Medical Oncologist and Research Fellow at Dana-Farber Cancer Institute, shared a post on X/Twitter:
“Final analysis of the PEONY phase 3 trial published on Nature Communications. Among 329 Asian patients with HER2+ BC, the addition of pertuzumab to perioperative treatment led to meaningful improvement in 5-year EFS (Δ11.1%), with benefit both in patients with pathologic complete response (pCR) and RD. ”
Source: Paolo Tarantino/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 18, 2024, 17:31
Nov 18, 2024, 17:22
Nov 18, 2024, 17:20
Nov 18, 2024, 17:13
Nov 18, 2024, 16:55
Nov 18, 2024, 16:50
Nov 18, 2024, 16:36